当前位置: 首页 >> 检索结果
共有 5162 条符合本次的查询结果, 用时 3.2129384 秒

1. Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial.

作者: Jean Y Tang.;M Peter Marinkovich.;Karen Wiss.;Daniel McCarthy.;Amanda Truesdale.;Albert S Chiou.;Edward Eid.;Joyce K McIntyre.;Irene Bailey.;Louise K Furukawa.;Emily S Gorell.;Nicki Harris.;Rohit K Khosla.;H Peter Lorenz.;Ying Lu.;Jaron Nazaroff.;I Dmitriy Grachev.;Amanda J Moore.
来源: Lancet. 2025年406卷10499期163-173页
Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genetic skin disease caused by mutations in the COL7A1 gene encoding type VII collagen. Individuals with RDEB have fragile skin and most develop large, chronic wounds. The aim of the VIITAL study was to evaluate the efficacy and safety of a one-time surgical application of prademagene zamikeracel in wound healing.

2. Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial.

作者: Thomas Blevins.;Dominik Dahl.;Federico C Pérez Manghi.;Sreenivasa Murthy.;Ramon Ortiz Carrasquillo.;Xiaoqi Li.;Annette M Chang.;Molly C Carr.;Michelle Katz.
来源: Lancet. 2025年405卷10497期2290-2301页
Insulin efsitora alfa (efsitora), a once-weekly basal insulin, has the potential to reduce the treatment burden of people with type 2 diabetes who require insulin. We aimed to assess the efficacy and safety of once-weekly efsitora compared with insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin.

3. Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial.

作者: Athena Philis-Tsimikas.;Richard M Bergenstal.;Timothy S Bailey.;Hideaki Jinnouchi.;James R Thrasher.;Liza Ilag.;Jit Mitra.;Kristen Syring.;Rebecca J Threlkeld.
来源: Lancet. 2025年405卷10497期2279-2289页
Once-weekly insulin efsitora alfa (efsitora) is in development for the treatment of people with diabetes. The aim of the current study was to assess the efficacy and safety of once-weekly efsitora compared with daily insulin degludec (degludec) in adults with type 2 diabetes using basal insulin.

4. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.

作者: Kirsten Dahl.;Søren Toubro.;Sohan Dey.;Ruben Duque do Vale.;Anne Flint.;Agnes Gasiorek.;Arne Heydorn.;Ania M Jastreboff.;Cassandra Key.;Signe Beck Petersen.;Andreas Vegge.;Kasper Adelborg.
来源: Lancet. 2025年406卷10499期149-162页
Amycretin is a novel, unimolecular GLP-1 and amylin receptor agonist. The aim of this study was to investigate the safety, tolerability, pharmacokinetics, and effects on bodyweight of subcutaneous amycretin administered over a treatment period of up to 36 weeks in participants with overweight or obesity.

5. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.

作者: Agnes Gasiorek.;Arne Heydorn.;Sanaz Gabery.;Julie B Hjerpsted.;Katrine Kirkeby.;Thomas Kruse.;Signe B Petersen.;Søren Toubro.;Andreas Vegge.;Cassandra Key.
来源: Lancet. 2025年406卷10499期135-148页
GLP-1 receptor agonists and amylin receptor agonists have shown clinically relevant weight loss and glucose-lowering effects in people with overweight, obesity, and type 2 diabetes. Amycretin is a novel, single-molecule GLP-1 receptor and amylin receptor agonist. We aimed to investigate the safety, tolerability, pharmacokinetic properties, and pharmacodynamic effects of single ascending doses (part A) and multiple ascending doses (parts B and C/D) of amycretin in adult participants with overweight or obesity.

6. Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial.

作者: Ali T Taher.;Hanny Al-Samkari.;Yesim Aydinok.;Martin Besser.;Audra N Boscoe.;Jayme L Dahlin.;Gonzalo De Luna.;Jeremie H Estepp.;Sarah Gheuens.;Keely S Gilroy.;Andreas Glenthøj.;Ai Sim Goh.;Varsha Iyer.;Antonis Kattamis.;Sandra R Loggetto.;Susan Morris.;Khaled M Musallam.;Kareem Osman.;Paolo Ricchi.;Eduardo Salido-Fiérrez.;Sujit Sheth.;Feng Tai.;Heather Tevich.;Katrin Uhlig.;Rolandas Urbstonaitis.;Vip Viprakasit.;Maria Domenica Cappellini.;Kevin H M Kuo.; .
来源: Lancet. 2025年406卷10498期33-42页
Non-transfusion-dependent (NTD) thalassaemia is characterised by ineffective erythropoiesis and haemolytic anaemia, leading to long-term complications, poor quality of life, and early mortality. No oral disease-modifying therapies are approved for β-thalassaemia and no agents are approved for α-thalassaemia. The objective of this study was to evaluate the efficacy and safety of mitapivat, an oral activator of pyruvate kinase, in adults with NTD α-thalassaemia or NTD β-thalassaemia.

7. Community-based mentoring to reduce maternal and perinatal mortality in adolescent pregnancies in Sierra Leone (2YoungLives): a pilot cluster-randomised controlled trial.

作者: Cristina Fernandez Turienzo.;Lucy November.;Mangenda Kamara.;Osman Conteh.;Philemon Kamara.;Appiah M Kingsford.;Peter J S Koroma.;Michael Munu.;Alexandra E Ridout.;Betty Sam.;Paul T Seed.;Suzanne Thomas.;Prince T Williams.;Andrew H Shennan.;Jane Sandall.; .
来源: Lancet. 2025年405卷10497期2302-2312页
Sierra Leone has very high maternal and neonatal mortality rates, and a large proportion of these deaths occur in adolescents, a particularly vulnerable group, and is usually driven by poverty, lack of education, and sparse employment opportunities. We evaluated the feasibility and potential effects of a community-based mentoring intervention from pregnancy up to 1 year after birth to inform a subsequent larger trial aiming to reduce mortality among adolescent girls and their newborns (2YoungLives).

8. Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trial.

作者: Ujjal Mallick.;Kate Newbold.;Matthew Beasley.;Kate Garcez.;Jonathan Wadsley.;Sarah J Johnson.;Tim Stephenson.;Mark Gaze.;Andrew Goodman.;Sarah Jefferies.;Suganya Sivabalasingham.;Nicholas Slevin.;David P Wilkinson.;Elena Macias-Fernandez.;Danielle Power.;Tom Roques.;Lesley Speed.;Christopher Nutting.;George Mochloulis.;Georgina Gerrard.;Charles Candish.;Sally Morgan.;Devashish Tripathi.;Peter Truran.;Claire Arthur.;Andrzej Wieczorek.;Krishnaswamy Madhavan.;Jillian Maclean.;David Boote.;Dae Kim.;Abigail Pascoe.;Gayani Pitiyage.;Sharon Forsyth.;Emily Ambrose.;Elizabeth Chang.;Kate Farnell.;Allan Hackshaw.
来源: Lancet. 2025年406卷10498期52-62页
Patients with differentiated thyroid cancer can often be treated with postoperative radioiodine (also called radioiodine ablation) after total thyroidectomy. The IoN trial was designed to assess whether recurrence-free survival was non-inferior after no ablation compared with ablation in patients with low-risk differentiated thyroid cancer.

9. Surgery versus corticosteroid injection for carpal tunnel syndrome (DISTRICTS): an open-label, multicentre, randomised controlled trial.

作者: Wijnand A C Palmbergen.;Roy Beekman.;A Marijne Heeren.;Bart F L van Nuenen.;Tim W H Alleman.;Esther Verstraete.;Korné Jellema.;Wim I M Verhagen.;Leo H Visser.;Godard C W de Ruiter.;Diederik van de Beek.;Corianne A J M de Borgie.;Johannes A Bogaards.;Rob M A de Bie.;Camiel Verhamme.; .
来源: Lancet. 2025年405卷10495期2153-2163页
Surgery and corticosteroid injections are established treatments for carpal tunnel syndrome, but the optimal treatment strategy remains unclear. This study aimed to compare starting treatment with surgery versus starting with a corticosteroid injection.

10. Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial.

作者: Sheela Rao.;Emmanuelle Samalin-Scalzi.;Ludovic Evesque.;Meher Ben Abdelghani.;Federica Morano.;Amitesh Roy.;Laetitia Dahan.;Stefano Tamberi.;Amandeep Singh Dhadda.;Mark P Saunders.;Nathalie Casanova.;Rosine Guimbaud.;Astrid Lievre.;Joan Maurel.;Marwan Fakih.;Chuan Tian.;Jill Harrison.;Mark M Jones.;Mark Cornfeld.;Jean-Philippe Spano.;Pauline Rochefort.; .
来源: Lancet. 2025年405卷10495期2144-2152页
Retifanlimab has activity in programmed death ligand 1-positive advanced squamous cell anal carcinoma (SCAC) that has progressed on platinum chemotherapy. We aimed to prospectively assess the benefit of adding retifanlimab to initial carboplatin-paclitaxel for this disease.

11. Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study.

作者: Alice P Chen.;Geraldine O'Sullivan Coyne.;Pamela L Wolters.;Staci Martin.;Said Farschtschi.;Ignacio Blanco.;Zhongping Chen.;Luiz Guilherme Darrigo.;Marica Eoli.;James R Whittle.;Yoshihiro Nishida.;Rosa Lamarca.;Randolph de la Rosa Rodriguez.;Ayo Adeyemi.;Idoia Herrero.;Nereida Llorente.;Scott J Diede.;Eva Dombi.;Pierre Wolkenstein.; .
来源: Lancet. 2025年405卷10496期2217-2230页
Currently, no worldwide approved therapies exist for adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas. The KOMET study aimed to evaluate selumetinib (ARRY-142886, AZD6244) efficacy and safety in this population.

12. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.

作者: Luis Paz-Ares.;Hossein Borghaei.;Stephen V Liu.;Solange Peters.;Roy S Herbst.;Katarzyna Stencel.;Margarita Majem.;Mehmet Ali Nahit Şendur.;Grzegorz Czyżewicz.;Reyes Bernabé Caro.;Ki Hyeong Lee.;Melissa L Johnson.;Nuri Karadurmuş.;Christian Grohé.;Sofia Baka.;Tibor Csőszi.;Jin Seok Ahn.;Raffaele Califano.;Tsung-Ying Yang.;Yasemin Kemal.;Marcus Ballinger.;Vaikunth Cuchelkar.;Vilma Graupner.;Ya-Chen Lin.;Debasis Chakrabarti.;Kamalnayan Bhatt.;George Cai.;Robert Iannone.;Martin Reck.; .
来源: Lancet. 2025年405卷10495期2129-2143页
Despite improved efficacy with first-line immune checkpoint inhibitors plus platinum-based chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC), survival remains poor. In this study, we aimed to compare lurbinectedin plus atezolizumab and atezolizumab alone as maintenance therapies in patients with ES-SCLC without progression after induction therapy with atezolizumab, carboplatin, and etoposide.

13. Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.

作者: Alexander B Olawaiye.;Laurence Gladieff.;David M O'Malley.;Jae-Weon Kim.;Gabriel Garbaos.;Vanda Salutari.;Lucy Gilbert.;Linda Mileshkin.;Alix Devaux.;Elizabeth Hopp.;Yong Jae Lee.;Ana Oaknin.;Mariana Scaranti.;Byoung-Gie Kim.;Nicoletta Colombo.;Michael E McCollum.;Connie Diakos.;Andrew Clamp.;Aliza L Leiser.;Boglárka Balázs.;Bradley J Monk.;Giuseppa Scandurra.;Emily McClung.;Emilie Kaczmarek.;Brian Slomovitz.;Helena De La Cueva.;Aknar Freire de Carvalho Calabrich.;Chiara Cassani.;Benoit You.;Toon Van Gorp.;Cristina Churruca.;Giuseppe Caruso.;Shibani Nicum.;Andrea Bagaméri.;Grazia Artioli.;Lubomir Bodnar.;Sokbom Kang.;Ignace Vergote.;Amanda Kesner-Hays.;Hristina I Pashova.;Sachin G Pai.;Iulia Cristina Tudor.;Adrian M Jubb.;Domenica Lorusso.
来源: Lancet. 2025年405卷10496期2205-2216页
Relacorilant, a first-in-class selective glucocorticoid receptor antagonist, increases a tumour's sensitivity to chemotherapy by reducing cortisol signalling. This study aimed to show whether the addition of relacorilant to nab-paclitaxel improves progression-free and overall survival in females with platinum-resistant ovarian cancer.

14. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.

作者: Changsong Qi.;Chang Liu.;Zhi Peng.;Yanqiao Zhang.;Jia Wei.;Wensheng Qiu.;Xiaotian Zhang.;Hongming Pan.;Zuoxing Niu.;Meng Qiu.;Yanru Qin.;Weijia Fang.;Feng Ye.;Ning Li.;Tianshu Liu.;Anwen Liu.;Xizhi Zhang.;Changlu Hu.;Jun Zhang.;Jiuwei Cui.;Xiaoyan Lin.;Shubin Wang.;Jian Zhang.;Tongyu Lin.;Xiujuan Qu.;Xianglin Yuan.;Jifang Gong.;Jian Li.;Wanwan Gao.;Lun Gai.;Yumeng Wang.;Daijing Yuan.;Zonghai Li.;Lin Shen.
来源: Lancet. 2025年405卷10494期2049-2060页
Claudin-18 isoform 2 (CLDN18.2) has emerged as a promising therapeutic target in gastric or gastro-oesophageal junction cancer. Satricabtagene autoleucel (satri-cel; also known as CT041), an autologous CLDN18.2-specific chimeric antigen receptor (CAR) T-cell therapy, showed encouraging activity in previously treated patients with advanced gastric or gastro-oesophageal junction cancer in phase 1 clinical trials. In this Article, we report the primary results from the phase 2 pivotal trial (CT041-ST-01) investigating the efficacy and safety of satri-cel for gastric or gastro-oesophageal junction cancer.

15. Safety and efficacy of low-intensity versus standard monitoring following intravenous thrombolytic treatment in patients with acute ischaemic stroke (OPTIMISTmain): an international, pragmatic, stepped-wedge, cluster-randomised, controlled non-inferiority trial.

作者: Craig S Anderson.;Debbie Summers.;Menglu Ouyang.;Yi Sui.;Brenda Johnson.;Laurent Billot.;Alejandra Malavera.;Roland Faigle.;Paula Muñoz-Venturelli.;Diana Day.;Xiaoqiu Liu.;Qiang Li.;Lili Song.;Thompson G Robinson.;Francisca González.;Francisca Urrutia-Goldsack.;Michael Iacobelli.;Michelle Montalbano.;April Pruski.;Candice Delcourt.;Alice C Durham.;Ahtasam Ebraimo.;Ha Hong Van Ta.;Pratiti Ghosh.;Ann Leonhardt-Caprio.;Huy Thang Nguyen.;Mai Duy Ton.;Stephen Jan.;Hueiming Liu.;Richard I Lindley.;Antonio Arauz.;Andrés Mercado.;Wan Asyraf Wan Zaidi.;Pooja Khatri.;Xia Wang.;Victor C Urrutia.; .
来源: Lancet. 2025年405卷10493期1909-1922页
The universally accepted best practice protocol for monitoring patients who receive intravenous thrombolysis for acute ischaemic stroke was established in the 1990s. However, the protocol is burdensome for nurses, disrupts the sleep of patients, and is potentially less relevant in patients at low risk of symptomatic intracerebral haemorrhage. We aimed to assess whether implementing a low-intensity monitoring protocol would be as safe and effective as standard high-intensity monitoring for patients with acute ischaemic stroke at low risk.

16. Comparison of supplemental breast cancer imaging techniques-interim results from the BRAID randomised controlled trial.

作者: Fiona J Gilbert.;Nicholas R Payne.;Iris Allajbeu.;Lim Yit.;Sarah Vinnicombe.;Iain Lyburn.;Nisha Sharma.;Will Teh.;Jonathan James.;Archana Seth.;Tamara Suaris.;Reena Aggarwal.;Miaad Al-Attar.;Sarah Savaridas.;Antonis Antoniou.;Paul Pharoah.;Stephen Duffy.
来源: Lancet. 2025年405卷10493期1935-1944页
It is not known which supplemental imaging technique is most beneficial for women with dense breasts attending breast screening. This study compares abbreviated MRI, automated whole breast ultrasound (ABUS), and contrast-enhanced mammography versus standard of care in women with dense breasts and a negative mammogram. We report on interim results from the first round of supplemental imaging.

17. ACURATE neo2 valve versus commercially available transcatheter heart valves in patients with severe aortic stenosis (ACURATE IDE): a multicentre, randomised, controlled, non-inferiority trial.

作者: Raj R Makkar.;Ravi K Ramana.;Eric Gnall.;Basel Ramlawi.;Wen Cheng.;Pantelis Diamantouros.;Srinivasa Potluri.;Neal Kleinman.;Aakriti Gupta.;Tarun Chakravarty.;Sanjay Samy.;Andrew Rassi.;Vivek Rajagopal.;Steven Yakubov.;Paul Sorajja.;Dhairya Patel.;Santiago Garcia.;Pradeep Yadav.;Vinod Thourani.;John Wang.;Michael Rinaldi.;Samir Kapadia.;Ron Waksman.;John Webb.;Claire Ben Ren.;John Gregson.;Rodrigo Modolo.;Janarthanan Sathananthan.;Michael J Reardon.; .
来源: Lancet. 2025年405卷10494期2061-2074页
ACURATE neo2 is an open-cell, supra-annular, self-expanding transcatheter heart valve that is commercially available in over 50 countries but has not previously been evaluated in a randomised trial. ACURATE-IDE aimed to prospectively evaluate the safety and efficacy of transcatheter aortic valve replacement (TAVR) with the ACURATE neo2 valve compared with commercially available valves for the treatment of severe symptomatic aortic stenosis.

18. Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies.

作者: Beryl B Cummings.;Mark P Joing.;Page R Bouchard.;Mark N Milton.;Peter F Moesta.;Vyas Ramanan.;Andrew Lane.;Joe Hirman.;John W Trauger.;Eleftheria Maratos-Flier.;Andrei Voznesensky.;Igor Splawski.;Amitabh V Nimonkar.;Meghan M Flaherty.;B Alexander Yi.;Daniel Meyers.;Francois Huet.;Sukhdeep K Sahambi.;Denise P Yates.;Douglas Hom.;Markus Hinder.;Craig T Basson.;Chris O'Donnell.;Evan S Siegelman.;Chris E Garrett.;Joshua Lehrer-Graiwer.;Rebecca A Juliano.;Ethan J Weiss.
来源: Lancet. 2025年405卷10493期1923-1934页
Genetic studies have established angiopoietin-related protein 4 (ANGPTL4) as a key regulator of triglyceride metabolism and a promising target to reduce atherosclerotic cardiovascular disease (ASCVD) risk beyond traditional risk factors. Human ANGPTL4 loss-of-function shows no adverse consequences and is associated with reduced triglycerides and remnant cholesterol, and a reduced risk of type 2 diabetes and ASCVD. Nonetheless, development of ANGPTL4 inhibitors has been delayed due to adverse findings in ANGPTL4-knockout mice fed a high saturated fat diet, including lipid accumulation in mesenteric lymph nodes, systemic inflammation, adverse clinical signs, and reduced survival. We previously reported the development and preclinical characterisation of MAR001, an ANGPTL4 inhibitory antibody. Here, we report a comprehensive safety assessment of ANGPTL4 inhibition, including novel analysis of genetic ANGPTL4 loss on mesenteric lymph node architecture in humans and two early-phase clinical trials.

19. Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.

作者: Gilbert Bensimon.;P Nigel Leigh.;Timothy Tree.;Andrea Malaspina.;Christine Am Payan.;Hang-Phuong Pham.;Pieter Klaassen.;Pamela J Shaw.;Ahmad Al Khleifat.;Maria D M Amador.;Shahram Attarian.;Simon M Bell.;Stéphane Beltran.;Emilien Bernard.;William Camu.;Philippe Corcia.;Jean-Christophe Corvol.;Philippe Couratier.;Véronique Danel.;Rabab Debs.;Claude Desnuelle.;Aikaterini Dimitriou.;John Ealing.;Florence Esselin.;Marie-Céline Fleury.;George H Gorrie.;Aude-Marie Grapperon.;Adèle Hesters.;Raul Juntas-Morales.;Ivan Kolev.;Géraldine Lautrette.;Nadine Le Forestier.;Christopher J McDermott.;Nicolas Pageot.;François Salachas.;Nikhil Sharma.;Marie-Hélène Soriani.;Jemeen Sreedharan.;Juliette Svahn.;Nick Verber.;Annie Verschueren.;Ozlem Yildiz.;Carey M Suehs.;Safaa Saker-Delye.;Claudie Muller.;Christophe Masseguin.;Hana Hajduchova.;Janine Kirby.;Cecilia Garlanda.;Massimo Locati.;Henrik Zetterberg.;Bernard Asselain.;Ammar Al-Chalabi.; .
来源: Lancet. 2025年405卷10492期1837-1850页
Amyotrophic lateral sclerosis (ALS) is a life-threatening disease characterised by progressive loss of motor neurons with few therapeutic options. The MIROCALS study tested the hypothesis that low-dose interleukin-2 (IL-2LD) improves survival and function in ALS.

20. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.

作者: Thomas Yau.;Peter R Galle.;Thomas Decaens.;Bruno Sangro.;Shukui Qin.;Leonardo G da Fonseca.;Hatim Karachiwala.;Jean-Frederic Blanc.;Joong-Won Park.;Edward Gane.;Matthias Pinter.;Ana Matilla Peña.;Masafumi Ikeda.;David Tai.;Armando Santoro.;Gonzalo Pizarro.;Chang-Fang Chiu.;Michael Schenker.;Aiwu He.;Hong Jae Chon.;Joanna Wojcik-Tomaszewska.;Gontran Verset.;Qi Qi Wang.;Caitlyn Stromko.;Jaclyn Neely.;Prianka Singh.;Maria Jesus Jimenez Exposito.;Masatoshi Kudo.; .
来源: Lancet. 2025年405卷10492期1851-1864页
Patients with unresectable hepatocellular carcinoma have a poor prognosis, and treatments with long-term benefits are needed. We report results from the preplanned interim analysis of the CheckMate 9DW trial assessing nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresectable hepatocellular carcinoma in the first-line setting.
共有 5162 条符合本次的查询结果, 用时 3.2129384 秒